Esperion Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

• Esperion Therapeutics Inc ESPR.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of seven analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -22 cents to -11 cents per share.

• Revenue rose 52% to $51.63 million from a year ago; analysts expected $51.32 million.

• Esperion Therapeutics Inc's reported EPS for the quarter was a loss of 15 cents​.

• The company reported a quarterly loss of $29.52 million.

• Esperion Therapeutics Inc shares had risen by 33.9% this quarter and lost 26.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 57.6% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Esperion Therapeutics Inc is 6.50

This summary was machine generated from LSEG data November 7 at 02:47 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)